- Surface Oncology (NASDAQ:SURF) has entered into a clinical trial collaboration with Roche Holdings AG (OTC:RHHBY) to evaluate former’s SRF388, anti-IL-27 antibody, in combination with Roche’s atezolizumab and bevacizumab in patients with treatment-naïve hepatocellular carcinoma (HCC).
- Atezolizumab plus bevacizumab has been shown to improve overall survival significantly and is the new standard of care for unresectable or metastatic HCC.
- “This collaboration leverages Roche’s deep experience in hepatocellular carcinoma and Surface’s commitment to rationally and rapidly develop SRF388, a first-in-class antibody against IL-27, to provide a meaningful benefit to patients with liver cancer,” said Surface Oncology chief medical officer Alison O’Neill.
- Price Action: SURF shares are down 1.68% at $8.91 during the market session on the last check Friday.
Dow Turns Higher; Crude Oil Rises Over 3%
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining over 80 points on Tuesday.
The Dow traded up 0.05% to 33,906.31 while the NASDAQ rose 0.69% to 11,969.79. The S&P 500 also rose, gaining, 0.40% to 4,127.37.
